NASDAQ: QLGNQualigen Therapeutics Inc Stock
$0.32+0.02 (+6.67%)
Updated Apr 23, 2024
QLGN Price
$0.32
Fair Value Price
-$0.18
Market Cap
$1.99M
52 Week Low
$0.28
52 Week High
$1.26
P/E
-0.12x
P/B
-0.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.97
Operating Cash Flow
-$10M
Beta
0.26
Next Earnings
May 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A
QLGN Overview
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QLGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QLGN ($0.32) is overvalued by 278.06% relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QLGN ($0.32) is not significantly undervalued (278.06%) relative to our estimate of its Fair Value price of -$0.18 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QLGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QLGN due diligence checks available for Premium users.
Be the first to know about important QLGN news, forecast changes, insider trades & much more!
QLGN News
Valuation
QLGN fair value
Fair Value of QLGN stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
-$0.18
Undervalued by
280.88%
QLGN ($0.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QLGN ($0.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QLGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QLGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
16.46x
Market
41.92x
QLGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.94x
Industry
5.93x
QLGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
QLGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.0M
Liabilities
$4.1M
Debt to equity
-1.97
QLGN's short-term liabilities ($4.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QLGN's short-term assets ($1.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QLGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QLGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.7M
Investing
$235.4k
Financing
-$110.0k
QLGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QLGN vs Biotech Stocks
Qualigen Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.